Evidence map›Paper›PMID 39099483›Full record

ArticleInternational journal of health policy and management2024

Effect of Cost-Exemption Policy on Treatment Interruption in Patients With Newly Diagnosed Pulmonary Tuberculosis in South Korea.

Sang Chul Lee, Jae Kwang Lee, Hyun Woo Ji, Jung Mo Lee, Seon Cheol Park, Chang Hoon Han

Abstract read
In one paragraph

Article in International journal of health policy and management, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sang Chul LeeDivision of Pulmonology and Allergy, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, South Korea.ORCID 0000-0001-5318-6804
Jae Kwang LeeDepartment of Research and Analysis, National Health Insurance Service Ilsan Hospital, Goyang, South Korea.ORCID 0000-0002-8480-8853
Hyun Woo JiDivision of Pulmonology and Allergy, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, South Korea.ORCID 0000-0002-2219-6329
Jung Mo LeeDivision of Pulmonology and Allergy, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, South Korea.ORCID 0000-0002-9972-8506
Seon Cheol ParkDivision of Pulmonology and Allergy, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, South Korea.ORCID 0000-0002-7926-1945
Chang Hoon HanDivision of Pulmonology and Allergy, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, South Korea.ORCID 0000-0002-4664-8924

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn 2021, South Korea had the highest incidence rate (49 per 100 000 population) and the third highest mortality rate (3.8 per 100 000 population) due to pulmonary tuberculosis (TB) among Organization for Economic Co-operation and Development countries. Notably, premature interruption of TB treatment interferes with TB control efforts. Therefore, we examined the effect of the co-payment waiver on treatment interruption and mortality among patients with pulmonary TB in South Korea.

methodsPatients who had newly treated TB in South Korea from 2013 to 2019 were selected from the nationwide data of the entire Korean National Health Insurance Service (NHIS) population. The effects of policy implementation on treatment adherence and mortality rates depending on treatment interruption history were evaluated.

resultsIn total, 73 116 and 1673 patients with drug-susceptible (DS) and multidrug-resistant (MDR) pulmonary TB, respectively, were included in the final study population. After implementing the cost-exemption policy, the treatment interruption rate tended to decrease in the continuation phase in the DS-TB group (slope change: -0.097,

conclusionImplementing the cost-exemption policy effectively reduced the treatment interruption rate among patients with DS pulmonary TB.

Indexed as

Antitubercular AgentsTuberculosis, PulmonaryAdolescentAdultAgedFemaleHealth PolicyHumansMaleMiddle AgedRepublic of KoreaTreatment InterruptionTuberculosis, Multidrug-ResistantYoung AdultAntitubercular AgentsAdministrative DataComplianceKoreaMortalityRisk factorsTuberculosis

Identifiers

PMID39099483
PMCPMC11365073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.